Summary Prognostic information is essential for the evaluation, judgement and optimal treatment of patients with squamous cell cancers (SCCs) 
Squamous cell cancers (SCCs) of the upper aerodigestive tract represent 5% of newly diagnosed cancers in the Western world (Schneiderman, 1978) . Traditional (Zarbo & Crissman, 1988) , the TNM (UICC staging) system is an imperfect prognostic indicator. Similarly, routine histomorphic grading systems and pathological appearances are of some benefit to the clinician in predicting clinical outcome (Fletcher, 1980) . Grading of SCCs is meaningful, although not the main determinant upon which treatment is based. Indeed, pathological criteria are subjective, often poorly standardised and must be regarded as relatively crude approximations of tumour cell kinetics and biological behaviour.
Evidence from several sources suggests that the degree of cellular proliferation within tumours holds some promise of enabling an estimate of their biological aggression (Young et al., 1987; Sledge et al., 1988) . Estimation of the labelling index (LI) by in vitro incorporation by tumour fragments of tritiated thymidine has been a reliable, albeit long and tedious, technique which has yielded important information in many types of cancer, confirming the clinical wisdom that fast growing cancers are more rapidly fatal than slowly growing ones (Tubiana & Courdi, 1989) . For patients with breast cancer, it has been suggested that the number of mitotic figures present is the most important prognostic variable .
The advent of monoclonal antibodies to various cellular antigens, oncogenes and oncoproteins has provided a novel, relatively quick, reproducible and simple means of studying various characteristics of the malignant phenotype. The Ki-67 monoclonal antibody recognises a nuclear antigen present in proliferating cells, but absent in resting cells (Gerdes et al., 1983) . Since its original description by Gerdes et al. (1983) , Ki-67 antibody has been a valuable tool for estimating the proportion of proliferating cells in a number of tumour types (Gerdes et al., 1986; Shepherd et al., 1988) . Gerdes' group has recently demonstrated a highly significant correlation between the proportion of Ki-67 positive cells and the histologic classification of lymphomas into high and low grade malignancies (Gerdes et al., 1984) .
Enhanced expression of epidermal growth factor receptors and transferrin receptors is known to be associated with cellular proliferation (Osborne et al., 1982; Trowbridge & Omary, 1981) . The EGF receptor is a 170kDa transmembrane glycoprotein whose function is to bind the mitogen EGF and to transduce this signal across the cell membrane to the cytoplasm (King, 1985; Marks, 1987 (Stoscheck & King, 1986) . Several authors have recently reported a correlation between EGFR expression and poorer differentiated, more proliferative and invasive tumours (Sainsbury et al., 1985) . It is possible that receptor amplification results from local production of EGF or EGF-like proteins (Derynck et al., 1987) which enhance EGFR expression (Earp et al., 1986) . The presence of EGFR overexpression is recognised as a hallmark of SCCs (Yamamoto et al., 1986 , and in lung cancer can be of diagnostic value in distinguis} ing SCCs from non-SCC histologies. High intensity EGFR staining may also define more invasive subpopulations of SCC (Veale et al., 1987) .
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of binding transferrin molecules, essential for various intracellular enzyme systems (Newman et al., 1982) . TF receptors have a widespread distribution and have been described in various cell populations in vitro and in vivo (Sutherland et al., 1981; Shindelman et al., 1981 (Wada et al., 1979) .
Immunohistochemical analysis has demonstrated intense TF receptor expression in many carcinomas and in a limited number of noirnal tissues (Gatter et al., 1983) ; in some, a correlation between TF receptor expression and tumour grade or stage has been established (Wrba et al., 1989) . In contrast to the subjectivity associated with currently used prognostic criteria, analysis of solid tumours by flow cytometry (FCM) permits rapid, objective and quantitative evaluation of cellular DNA content (Merkel et al., 1987) .
Abnormal cellular DNA content (aneuploidy), a reflection of chromosomal instability, is a well-recognised and common feature of human cancer, and ploidy status appears to be an important determinant of clinical outcome at a number of cancer sites (Friedlander et al., 1984; Merkel et al., 1987 with squamous epithelial pearls, the tumour was graded as well differentiated. When keratinisation was present only in some areas of the tumour it was graded as poorly differentiated. When there appeared to be a fairly even mixture of keratinising areas and non-keratinising areas, the tumour was graded as moderately well differentiated. Some keratinisation was present in all of the tumours studied.
Immunohistochemistry
The Ki-67 antigen, EGF and TF receptors were identified by means of an indirect immunoperoxidase technique with murine monoclonal antibodies as previously described (Hsu et al., 1981) . The EGF receptor monoclonal antibody was raised from an epidermoid carcinoma cell line (A431) which expresses a high concentration of EGF receptors (Waterfield et al., 1982 Monoclonal Development Co., respectively). The HuLy-m9 antibody has a specificity equivalent to that of monoclonal antibody OKT9 (Panaccio et al., 1986 Epidermal growth factor receptor (EGFR) Staining for the EGFR was generally of similar degree and intensity to that demonstrated for the TFR expression. As was the case with TFR expression, all SCCs studied demonstrated EGFR expression to varying degrees. Normal (overlying) stratified squamous epithelium also demonstrated consistent expression of EGFR in the basal cell laye'r and membranous staining of scattered cells in the immediate suprabasal layer. There was only slight variation in staining intensity between different tumours apart from the same seven samples which demonstrated marked generalised TFR intensity. Immunoreactivity was often both cytoplasmic and membrane-bound, although in the more differentiated tumours a marked honeycomb pattern was seen in many cases. In samples which showed moderate to intense degrees of staining intensity, the staining was often more cytoplasmic than membrane-bound. The staining reaction was invariably most intense in cells at the invading tumour margin and in cells at the periphery of invading cellular islands (Figure 2 ). This was just as noticeable for the EGFR as it was for the TFR.
The relationship between EGFR reactivity and histologic grade is seen in Table L Ki-67 monoclonal antibody Figure 3 shows the relationship between nuclear reactivity obtained with Ki-67 antibody in cases with a low (0-10%), intermediate (10-30%) and high (>30%) growth fraction, and histological grade. Table I (Tubiana & Courdi, 1989) . Proliferative status has been most commonly studied in patients with breast cancer for whom it can be shown that a high proliferative rate is strongly linked not only to a short relapse-free and overall survival , but also to other conventional prognostic factors such as poor histological grade, oestrogen receptor negativity and DNA aneuploidy (McGurrin et al., 1987; Wrba et al., 1989) . Most recently, Bouzubar et al. (1989) have demonstrated mitotic activity. Many studies have now confirmed the adverse prognosis associated with cancers which have a high proliferative status, and the proliferative rate is generally held to be higher in metastases than in primary tumours of the same histology (Tubiana & Courdi, 1989) . In their study of the relationship of ploidy status, TFR and EGFR reactivity in breast cancer patients, Walker and Camplejohn (1986) demonstrated significant relationships between (a) DNA ploidy and percentage S-phase cells, (b) the degree of histologic differentiation and S-phase content and (c) the degree of TFR and EGFR expression and both ploidy status and S-phase fraction.
One of the few papers published on proliferation status in head and neck SCC patients concluded that patients with a tumour labelling index (LI) greater than 15.5% had a significantly poorer survival than patients with a lower tumour LI (P = 0.008) (Chauvel et al., 1989 ). Their results demonstrate that a high tumour proliferation rate is an additional independent prognostic factor in this disease.
Whether ploidy is a prognostic factor independent of other proliferation indices is currently unknown. In the case of breast cancer, several studies have now demonstrated that ploidy status and proliferation indices are independent prognostic factors (Goldsmith et al., 1987; Johnson et al., 1985) . De Braud et al. (1988) have recently reported the results of a prospective study of ploidy status in patients with advanced resectable head and neck SCCs. Their results demonstrate a significantly more favourable outlook in terms of relapse-free and overall survival for patients with diploid tumours. In our study, a number of factors hindered reliable assessment of percentage S-phase fraction of cells. We were able to obtain reliable estimates on relatively few specimens because aneuploidy was common and individual aneuploid peaks were often small compared to the height of the main (diploid) GI peak. This variable and possibly inaccurate derivation of S-phase fraction from FCM has been noted by others and in the interests of scientific accuracy, we chose not to pursue the issue further.
Well differentiated SCCs are characterised by proliferative cells at the periphery of the tumour and keratinised differentiated cells towards the centre (Ferenczy, 1982) . Previous studies using tritiated thymidine on the mouse SCC lung tumour model have demonstrated that the tumour periphery is composed of highly proliferative primitive cells which are the progenitors of the more differentiated cells in the central portion of the tumour (Williams & Nettesheim, 1973) . In their study of Ki-67 reactivity in patients with cervical SCCs, Brown et al. (1988) noted that the distribution of nuclear labelling varied from little to nil in central areas of cellular maturation and keratinisation to significantly high reactivity in the more actively proliferating peripheral portions. The same finding in our study was so striking that it is tempting to suggest that quantitation of the proportion of positively staining cells on the invading tumour margin may be a more significant prognostic guideline than an overall estimate of the proportion of Ki-67 positive cells in a given tumour.
Demonstration of the EGFR or the TFR in oral SCCs is clearly of limited value. Previous studies have already demonstrated that TFRs are widely distributed on the surface of many types of cancer cells (Gatter et al., 1983) , and that the over-expression of EGFR is a hallmark associated with SCCs (Merlino et al., 1985) . It is, however, worth reiterating that cells which strongly expressed the EGFR and TFR in our study invariably exhibited a high reactivity with the Ki-67 monoclonal antibody. Furthermore, there was a close spatial co-localisation of cells which expressed all three antigens. Our observation is consistent with the finding that expression of EGFR and TFR is found on actively divided cells and that the most actively proliferating cells occur on the periphery of invading tongues and islands of tumour tissue.
It is a reasonable postulate that those cells which are most actively invasive (i.e. proliferating) will express EGFR and TFR to the greatest extent. This is consistent with the strong correlation between Ki-67 immunoreactivity and TFR expression in a large study of breast carcinomas (Wrba et al., 1989 In any prospective study of head and neck SCCs, those graded as moderately differentiated will dominate in number. However, the designation that a tumour is moderately differentiated is of little, if any, prognostic value to the clinician, and our results highlight the great variation in proliferative status among these patients. As in our study, Walker and Camplejohn's (1986) ability to correlate expression of surface receptors with the degree of histological differentiation was somewhat confounded by the predominance of moderately differentiated tumours and a very small number of well differentiated ones. In the study by Sainsbury et al. (1985) , however, moderately differentiated breast cancers comprised a smaller proportion of cases, and a clear cut correlation between EGFR expression and poorly differentiated grading was demonstrated. Furthermore, Fitzpatrick et al. (1984) observed that the highest quantities of EGF binding sites were expressed in tumours that lacked oestrogen receptors -a factor known to be associated with aneuploidy, a high S-phase content and poorer differentiation. Neal et al. (1985) demonstrated that intense EGFR staining was related to poor differentiation of bladder cancers. The work of Veale et al. (1987) was also confounded by a very small number of well differentiated squamous lung cancers and failed to demonstrate any significant relationship between EGFR staining and degree of differentiation. However, they were able to demonstrate significantly stronger staining in 30 stage 3 tumours compared to 47 stage 1 and 2 tumours, and they suggested that the presence of high intensity EGFR staining was associated with biologically aggressive non-small cell lung cancers.
Further patient follow-up will obviously be important in determining whether intense staining for EGFR and TFR, combined with a high percentage reactivity with Ki-67 antibody and DNA aneuploidy, will ultimately define a subset of head and neck cancer patients with a poor clinical outcome.
